AIRTELAFRI₦6,300.00• 0.00%
DANGCEM₦1,066.70• 0.00%
MTNN₦825.00▲ 0.61%
BUAFOODS₦760.60• 0.00%
BUACEMENT₦297.00• 0.00%
SEPLAT₦16,000.10• 0.00%
ARADEL₦1,499.90• 0.00%
FIRSTHOLDCO₦138.00• 0.00%
HBMNG₦355.00• 0.00%
ZENITHBANK₦126.00▼ 1.33%
GTCO₦124.80▼ 2.27%
TRANSCOHOT₦290.50• 0.00%
STANBIC₦160.00▼ 2.14%
PRESCO₦2,045.30• 0.00%
NB₦75.00• 0.00%
NESTLE₦2,750.00• 0.00%
GEREGU₦825.70• 0.00%
UBA₦43.00▼ 0.35%
INTBREW₦10.00▲ 0.50%
ACCESSCORP₦28.50▲ 0.71%
DANGSUGAR₦67.50▲ 0.52%
TRANSPOWER₦178.00• 0.00%
FIDELITYBK₦21.05▲ 4.73%
ETI₦71.40• 0.00%
WEMABANK₦31.00• 0.00%
OKOMUOIL₦1,276.20• 0.00%
GUINNESS₦423.00• 0.00%
FCMB₦10.80▼ 1.82%
UNILEVER₦102.50• 0.00%
UACN₦184.00• 0.00%

GDN DESKTOP 1

Advertisement

Type 2 diabetes drug combats Parkinson’s

Diabetes . PHOTO: Newsmax.com

Diabetes drug. PHOTO: Newsmax.com

A diabetes drug could be a breakthrough treatment for stopping Parkinson’s disease in its tracks, a study suggests.People with Parkinson’s who took Exenatide – an existing diabetes medication – for around a year had better motor skills than those who took a placebo.

The results suggest the drug could halt decline in Parkinson’s patients rather than just relieving symptoms.Experts welcomed the University College London (UCL) research as a ‘particularly promising’ step in the search for a treatment to slow or stop the disease.
[ad]
The drug is modelled on the saliva of the Gila monster lizard and has been used since 2005 to treat Type 2 diabetes.The research is published in The Lancet on Friday and was funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Join Our Channels

Taboola Recommendation Widget